XNCR (Xencor) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 26, 2026)


XNCR Xencor Inc XNCR
52 GF Score
Price $14.75
GF Value $9.60
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Xencor Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Xencor's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

XNCR vs ORIC, ANNX, JANX: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Xencor's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xencor Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xencor's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Xencor's Margin of Safety % (DCF FCF Based) falls into.


XNCR
52GF Score
Xencor Inc XNCR
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Xencor (XNCR) Overvalued in 2026?

Based on GuruFocus' analysis, Xencor stock appears to be overvalued. The current stock price of $14.75 is trading 53.6% above its estimated GF Value™ of $9.60. GuruFocus considers Xencor to be Significantly Overvalued.

Key valuation signals for XNCR:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: $9.60 vs. price of $14.75 (53.6% above fair value)
  • GF Score™: 52/100 with 7 warning signs

No single metric tells the full story. See the XNCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xencor Business Description

Other Exchanges XE9:Germany
Address 465 North Halstead Street, Suite 200, Pasadena, CA, USA, 91107
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
52GF Score

Get the complete analysis for XNCR

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.75
Price
$9.60
GF Value